Accès gratuit
Med Sci (Paris)
Volume 25, Numéro 12, Décembre 2009
Anticorps monoclonaux en thérapeutique
Page(s) 1024 - 1032
Section I - De la conception à la production
Publié en ligne 15 décembre 2009
  1. Schneider CK. Monoclonal antibodies: regulatory challenges. Current Pharmaceutical Biotechnology 2008; 9 :431–8. [Google Scholar]
  2. Chartrain M, Chu L. Development and production of commercial therapeutic monoclonal antibodies in mammalian cell expression system: an overview of the current upstream technologies. Curr Pharm Biotechnol 2008; 9 : 447–67. [Google Scholar]
  3. Seamans TC, Fries S, Beck A, et al. Cell cultivation process transfer and scale up in support of the production of early clinical supplies of an anti-IGF-1R antibody (part I). BioProcess Int 2008; 3 : 26. [Google Scholar]
  4. Beck A, Klinguer-Hamour C, Bussat MC, et al. Peptides as tools and drugs for immunotherapies. J Pept Sci 2007; 13 : 588–602. [Google Scholar]
  5. Beck A, Wagner-Rousset E, Goetsch L, et al. Therapeutic antibodies: structure assessment by mass spectrometry from screening to clinical batches. Screening Trends Drug Discov 2008; 9 : 18–20. [Google Scholar]
  6. Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol 2008; 9 : 423–30. [Google Scholar]
  7. Beck A, Wagner-Rousset E, Bussat MC, et al. Trends in Glycosylation, Glycoanalysis and Glycoengineering of Therapeutic Antibodies and Fc-Fusion Proteins. Curr Pharm Biotechnol 2008; 9 : 482–501. [Google Scholar]
  8. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256 : 495–7. [Google Scholar]
  9. Morrison SL, Johnson MJ, Herzenberg LA, et al. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984; 81 : 6851–5. [Google Scholar]
  10. Jones PT, Dear PH, Foote J, et al. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986; 321 : 522–5. [Google Scholar]
  11. McCafferty J, Griffiths AD, Winter G, et al. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990; 348 : 552–4. [Google Scholar]
  12. Lonberg N, Taylor LD, Harding FA, et al. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 1994; 368 : 856–9. [Google Scholar]
  13. Green LL, Hardy MC, Maynard-Currie CE, et al. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat Genet 1994; 7 : 13–21. [Google Scholar]
  14. Ruuls SR, Lammerts van Bueren JJ, van de Winkel JG, et al. Novel human antibody therapeutics: the age of the Umabs. Biotechnol J 2008; 3 : 1157–71. [Google Scholar]
  15. Lonberg N. Fully human antibodies from transgenic mouse and phage display platforms. Curr Opin Immunol 2008; 20 : 450–9. [Google Scholar]
  16. Peipp M, Dechant M, Valerius T. Effector mechanisms of therapeutic antibodies against ErbB receptors. Curr Opin Immunol 2008; 20 : 436–3. [Google Scholar]
  17. Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther 2007; 7 : 1401–13. [Google Scholar]
  18. Salfeld JG. Isotype selection in antibody engineering. Nat Biotechnol 2007; 25 : 1369–72. [Google Scholar]
  19. Van der Neut Kolfschoten M., Schuurman J, Losen M, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007; 317 : 1554–7. [Google Scholar]
  20. Dillon TM, Ricci MS, Vezina C, et al. Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J Biol Chem 2008; 283 : 16206–15. [Google Scholar]
  21. Yoo EM, Wims LA, Chan LA, et al. Human IgG2 can form covalent dimers. J Immunol 2003; 170 : 3134–8. [Google Scholar]
  22. Liu YD, Chen X, Enk JZ, et al. Human IgG2 antibody disulfide rearrangement in vivo. J Biol Chem 2008; 283 : 29266–72. [Google Scholar]
  23. Presta LG. Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 2008; 20 : 460–70. [Google Scholar]
  24. Rother RP, Rollins SA, Mojcik CF, et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007; 25 : 1256–64. [Google Scholar]
  25. Natsume A, In M, Takamura H, et al. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res 2008; 68 : 3863–72. [Google Scholar]
  26. Angal S, King DJ, Bodmer MW, et al. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol Immunol 1993; 30 : 105–8. [Google Scholar]
  27. Kai M, Motoki K, Yoshida H, et al. Switching constant domains enhances agonist activities of antibodies to a thrombopoietin receptor. Nat Biotechnol 2008; 26 : 209–11. [Google Scholar]
  28. Wurch T, Lowe P, Caussanel V, et al. Development of Novel Protein Scaffolds as Alternatives to Whole Antibodies for Imaging and Therapy: Status on Discovery Research and Clinical Validation. Curr Pharm Biotechnol 2008; 9 : 502–9. [Google Scholar]
  29. Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008; 358 : 1109–17. [Google Scholar]
  30. Wagner-Rousset E, Bednarczyk A, Bussat MC, et al. The way forward, enhanced characterization of therapeutic antibody glycosylation: comparison of three level mass spectrometry-based strategies. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 872 : 23–37. [Google Scholar]
  31. Satoh M, Iida S, Shitara K. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin Biol Ther 2006; 6 : 1161–73. [Google Scholar]
  32. Hamilton SR, Gerngross TU. Glycosylation engineering in yeast: the advent of fully humanized yeast. Curr Opin Biotechnol 2007; 18 : 387–92. [Google Scholar]
  33. Anthony RM, Nimmerjahn F, Ashline DJ, et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008; 320 : 373–6. [Google Scholar]
  34. Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 2008; 20 : 471–8. [Google Scholar]
  35. Labrijn AF, Aalberse RC, Schuurman J. When binding is enough: nonactivating antibody formats. Curr Opin Immunol 2008; 20 : 479–85. [Google Scholar]
  36. Melmed GY, Targan SR, Yasothan U, et al. Certolizumab pegol. Nat Rev Drug Discov 2008; 7 : 641–2. [Google Scholar]
  37. Schneider CK, Kalinke U. Toward biosimilar monoclonal antibodies. Nat Biotechnol 2008; 26 : 985–90. [Google Scholar]
  38. Moon JY, Kim W, Kim JH, et al. A multicenter, randomized, open-label, therapeutic, and exploratory trial to evaluate the tolerability and efficacy of platelet glycoprotein IIb/IIIa receptor blocker (Clotinab) in high-risk patients with percutaneous coronary intervention. Yonsei Med J 2008; 49 : 389–99. [Google Scholar]
  39. Beck A, Bussat MC, Zorn N, et al. Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NS0 cells. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 819 : 203–18. [Google Scholar]
  40. Vlasak J, Ionescu R. Heterogeneity of Monoclonal Antibodies relvealed by charge-sensitive methods. Curr Pharm Biotechnol 2008; 9 : 468–81. [Google Scholar]
  41. Beck A, Wurch T, Corvaïa N. Editorial: therapeutic antibodies and derivatives: from the bench to the clinic. Curr Pharm Biotechnol 2008; 9 : 421–2. [Google Scholar]
  42. Swann PG, Tolnay M, Muthukkumar S, et al. Considerations for the development of therapeutic monoclonal antibodies. Curr Opin Immunol 2008; 20 : 493–9. [Google Scholar]
  43. Kim MS, Lee SH, Song MY, et al. Comparative analyses of complex formation and binding sites between human tumor necrosis factor-alpha and its three antagonists elucidate their different neutralizing mechanisms. J Mol Biol 2007; 374 : 1374–88. [Google Scholar]
  44. Aggarwal S. What’s fueling the biotech engine-2007. Nat Biotechnol 2008; 26 : 1227–33. [Google Scholar]
  45. Gires O. EpCAM, une protéine versatile impliquée dans l’oncogenèse. Med Sci (Paris) 2009; 25 : 449–50. [Google Scholar]
  46. Faye L, Champey Y. Plantes, médicaments et génétique : quelles applications pour demain ? Med Sci (Paris) 2008; 24 : 939–45. [Google Scholar]
  47. Beck A, Iver H, Reichert JM. European Medecines Agency workshop on biosimilar monoclonal antibodies Meeting Report (London, UK, July 2, 2009). mAbs-Landes Bioscience 2009; 5 : 394–416. ( [Google Scholar]
  48. Beck A, Cochet O, Wurch T. GlycoFi’s technology to control the glycosylation of recombinant therapeutic proteins. Expert Op Drug Discov 2010 (sous presse). [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.